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1Introduction
Malignant mesothelioma is a rare cancer usually originat-
ing from the lining cells of the pleural and peritoneal 
cavities [1]. Asbestos is by far the most important risk 
factor for mesothelioma; however, a background lifetime 
probability (i.e., the risk of getting the disease in the 
absence of exposure to asbestos) of about 3 per 10,000 
has been estimated [2, 3]. Hence, recent experimental 
and epidemiological studies have focused on other potential 
causal factors of mesothelioma, including: nonasbestiform 
mineral fibers (erionite; fluoro- edenite); carbon nanotubes; 
viruses (MC29 avian leukosis virus; SV40); metals; chronic 
serosal inflammation; and ionizing radiation [4].
The association between ionizing radiation and meso-
thelioma has been studied among nuclear power plant 
workers and among patients exposed to the diagnostic 
X- ray contrast medium ‘‘Thorotrast’’ or to external beam 
radiotherapy (EBRT) [5]. However, available evidence on 
the association between EBRT and mesothelioma is still 
controversial [5]. First, most studies were based on a 
limited number of mesothelioma cases. Second, there is 
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Abstract
We investigated the association between external beam radiotherapy (EBRT) 
and pleural and peritoneal mesothelioma among long- term (>5 years) solid 
cancer survivors. We analyzed data from the US Surveillance, Epidemiology, 
and End Results (SEER) program (1973–2012). We fitted survival models ad-
justed by age, gender, race, year, surgery, and relative risk of primary meso-
thelioma in the county of residence (proxy for individual asbestos exposure). 
We estimated hazard ratios [HR] with reference to nonirradiated patients. We 
distinguished between scattered and direct irradiation to study the dose–response. 
We observed 301 mesotheliomas (265 pleural; 32 peritoneal; 4 others) among 
935,637 patients. EBRT increased the risk of mesothelioma (any site; HR 1.34, 
95% CI 1.04–1.77). We observed an increased risk of pleural mesothelioma 
(HR for EBRT 1.34, 95% CI 1.01–1.77), but we did not find signs of a dose–
response relationship (HR for scattered irradiation 1.38; HR for direct irradiation 
1.23). On the  opposite, only direct peritoneal irradiation was associated with 
peritoneal mesothelioma (HR 2.20, 95% CI 0.99–4.88), particularly for latencies 
≥10 years (HR 3.28, 95% CI 1.14–9.43). A competing risks analysis revealed 
that the clinical impact of radiation- induced mesothelioma was limited by the 
high frequency of competing events. The cumulative incidence function of meso-
thelioma after 40 years of observation was very low (nonirradiated patients 
0.00032, irradiated patients 0.00055).EBRT might be a determinant of meso-
thelioma. Longer latency periods are associated with higher risks, while the 
dose–response seems nonlinear. The clinical impact of mesothelioma after EBRT 
for primary solid cancers is limited. 
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lack of knowledge on the possible dose–response relation-
ship. In a previous study, we reported an increased inci-
dence of mesothelioma after EBRT for prostate cancer 
[6]. Remarkably, we found suggestive evidence that the 
magnitude of the risk could depend on the distance of 
the mesothelium from the irradiated field. Indeed, we 
observed the higher relative risk for peritoneal mesothe-
lioma, which occurs within the irradiated field [6].
To provide further evidence of the association between 
EBRT and mesothelioma and to fill the knowledge gap 
on the dose–response, we conducted an analysis of meso-
thelioma incidence after EBRT for primary solid cancer 
using data from the from the US National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) 
Program. We also aimed at evaluating the clinical impact 
of radiation- induced mesotheliomas among EBRT patients.
Materials­and­methods
Study­population­and­follow-­up
We defined the cohort as adult (age>20 years) patients 
with a first primary solid cancer reported to one of the 
SEER registries. The SEER 9 Registries database was con-
sulted for the period between Jan 1, 1973 and Dec 31, 
1991, while the SEER 13 Registries database was used for 
the period between Jan 1, 1992 and Dec 31, 2012. We 
studied only cancer sites that were frequently (>10%) 
treated with EBRT. Because of the minimum latency period 
for radiation- induced solid neoplasms, we excluded subjects 
who survived <5 years after the primary diagnosis and 
we started the follow- up window after the fifth year of 
survival [7]. We removed from the cohort patients with 
a diagnosis of bone, soft tissue, nerve or “other endocrine” 
cancers because of uncertainty on the irradiated areas. 
Moreover, we excluded subjects with primary cancers of 
pleura, peritoneum, retroperitoneum, omentum, or other 
mesentery due to the possibility that these neoplasms were 
misdiagnosed mesotheliomas. We applied listwise deletion 
and we analyzed only subjects with complete information 
on radiotherapy, surgery, and county of residence. In this 
study, we did not consider subjects who had received 
radiotherapy treatments other than EBRT. On the one 
hand, this group could not be merged to the reference 
category (nonirradiated subjects) because there is not 
definitive evidence that these treatments are not associated 
with an increased risk of second cancer, for example,[8]. 
On the other hand, the number of cases (n = 20) observed 
was too limited to conduct separate analyses. Finally, we 
excluded those cancer sites with less than one expected 
case of mesothelioma (estimated based on the calendar 
year- , age- , sex- and race- specific mesothelioma rates 
observed in the SEER Registries database; see Table S1). 
A list of the studied primary cancer sites is presented in 
Table 1 alongside with the number of observed meso-
thelioma cases.
The follow- up time for each individual started 5 years 
after the first primary diagnosis and ended at the diagnosis 
of mesothelioma, incidence of a second malignancy other 
than mesothelioma, death, or at the end of the study 
(12/31/2012). Death or incidence of a second malignancy 
other than mesothelioma were treated as competing events 
and subjects lost to follow- up were right- censored. Also, 
we censored the follow- up at the age of 85 years due to 
the known under- ascertainment of second primary cancers 
after that age in the SEER registries [9].
This study was conducted in compliance with the 1964 
Helsinki declaration and its later amendments. Given the 
Table 1. Number of mesothelioma cases and classification of radiation dose to pleura and peritoneum based on primary cancer site.
Mesothelioma cases Dose
Primary cancer site Pleural (n = 265) Peritoneal (n = 32)
Other/unknown 
(n = 4) Pleura Peritoneum
Eye and orbit 2 0 0 Scattered Scattered
Oral cavity and pharynx 5 1 0 Direct Scattered
Larynx 7 0 0 Direct Scattered
Lung and bronchus 4 1 0 Direct Scattered
Breast 27 8 0 Direct Scattered
Stomach 2 0 0 Direct Direct
Rectum and rectosigmoid junction 19 2 0 Scattered Direct
Cervix uteri 1 1 0 Scattered Direct
Corpus uteri and uterus NOS 7 4 0 Scattered Direct
Prostate 186 14 4 Scattered Direct
Testis 5 1 0 Scattered Direct
Penis and other male genital organs 0 0 0 Scattered Direct
NOS, not otherwise specified.
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retrospective nature of this study conducted using register 
data, formal consent was not required.
Outcome­measures­and­case­definitions
We investigated the risk of mesothelioma occurring in 
any site, of pleural and peritoneal mesothelioma. As many 
patients of our cohort died during the study period or 
developed a second malignancy other than mesothelioma, 
we accounted for competing risks in our analysis [10]. 
To answer our main etiological research question on the 
causal association between EBRT and mesothelioma, we 
estimated the cause- specific hazard ratio (HR) of meso-
thelioma [10–12]. Then, to evaluate the clinical impact 
of the observed associations, we modeled the subhazard 
ratio [SHR] and the cumulative incidence function (CIF) 
of mesothelioma [10–12].
Exposure­and­covariates
Patients were classified according to whether or not they 
had received radiotherapy as a part of their initial treat-
ment for primary cancer. We compared patients who 
received EBRT (alone or in combination with other forms 
of radiotherapy) with those who were not treated with 
any form of radiotherapy. When studying specific meso-
thelioma sites, we further classified the exposure based 
on the presumed dose received by the mesothelium (see 
Table 1) [13, 14]. We created the following three categories 
of exposure to radiation:
1. unexposed, did not receive any radiotherapy;
2. scattered exposure, primary cancer located far (≥3 cm) 
from the pleura and thoracic/cervical lymph nodes 
unlikely to be irradiated during the initial treatment 
(study of pleural mesothelioma), or primary cancer 
located far from the peritoneum (study of peritoneal 
mesothelioma);
3. direct, primary cancer located next (<3 cm) or within 
the pleura and/or thoracic/cervical lymph nodes likely 
to be irradiated (study of pleural mesothelioma), or 
primary cancer located next or within the peritoneum 
(study of peritoneal mesothelioma).
Covariates to be included in the multivariable models 
were selected a priori and included: age, sex, calendar 
year, race (white, black, other), and surgery of primary 
cancer.
No individual information is available in the SEER 
database on the exposure to asbestos, the main determi-
nant of mesothelioma [1]. As the uses of asbestos tended 
to be clustered and pleural mesothelioma mortality at the 
population level has been proposed as a suitable indicator 
of asbestos exposure [15, 16] we conducted a spatial 
analysis to derive a proxy exposure variable. At first, we 
estimated the relative risk (RR) of primary mesothelioma 
among males – the fraction of cases attributable to asbestos 
among females is lower [1, 17]) – by county using the 
SEER 13 Registries data (1992–2012). Then, we classified 
each subject according to the county’s RR of mesothe-
lioma, based on the county of residence at the time of 
the primary diagnosis.
Latency (time since first exposure) was considered as 
a possible effect modifier of the relationship between EBRT 
and mesothelioma because the risk of cancer increases 
for decades after radiation exposure [7, 13]. Latency was 
calculated with reference to the date of the primary diag-
nosis and grouped into two categories: 5–10 years; more 
than 10 years.
Statistical­analysis
In the descriptive tables, continuous variables were 
expressed as mean and standard deviation (SD), whereas 
categorical variables were summarized as number and 
percentages.
Using survival time as the main temporal axis, we fitted 
Cox proportional hazards regression models to estimate 
cause- specific HR and Fine and Gray competing risks regres-
sion models to estimate SHR [18]. We additionally adapted 
regression models including product terms between the 
exposure of interest and the latency period, but due to the 
limited number of peritoneal mesothelioma cases among 
subjects who received scattered radiation (n = 3), this cat-
egory was not retained in this analysis. We estimated the 
CIF of mesothelioma in any site through flexible parametric 
survival models for competing risk [19]. In these models, 
three separate baseline hazards (three degrees of freedom 
each) were allowed to model mesothelioma, other malignan-
cies, and death incidence. The exposure variables of interest 
were included in the models as time varying covariates (three 
degree of freedom) and we allowed for a different effect 
of the covariates across the competing events. All the analyses 
were adjusted by sex and age (parameterized as age and 
squared age). When investigating the risk of any mesothe-
lioma and pleural mesothelioma, we further conducted 
multivariable regression models additionally adjusted by race 
(white, black, or other), year of primary cancer diagnosis, 
primary cancer surgery, and county’s mesothelioma RR. 
Fully adjusted HR were not estimated for peritoneal meso-
thelioma due to the limited number of analyzed cases. As 
a sensitivity analysis, we fitted a series of bivariate regression 
models including the variable for the peritoneal dose and 
the potential confounders one at time.
We fitted an additional set of Cox regression models 
assuming shared- frailty (gamma- distributed latent random 
effects) by primary cancer site to model within- group 
4 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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correlation. However, the theta parameter for random 
effects never approached the statistical significance 
(P < 0.05) and the estimates for the fixed part of the 
models (i.e., the HR) were not materially changed by the 
inclusion of the random parameters. Hence, our final 
models did not assume shared- frailty by primary cancer.
The RR of mesothelioma by county were estimated 
using the Besag–York–Mollie (BYM) model, which allows 
for both heterogeneous and spatially structured random 
effects [20]. Additional details on the BYM model are 
presented in Supplementary Resource 1 alongside with 
maps showing the distribution of standardized incidence 
ratios and RR (Fig. S1 and 2).
Figures on cancer and individual records were obtained 
using SEER*Stat software 8.2.1. We used Stata 12.1 SE 
(Stata Corporation, Texas, TX) software package for the 
main analysis.
Results
As shown in Figure 1, the SEER registries included 3,416,054 
cases of primary cancer among subjects aged between 20 
and 84 years. In the present analysis, we considered only 
frequently irradiated sites with at least one expected meso-
thelioma case during the study period, including: eye or 
orbit; oral cavity and pharynx; larynx; lung and bronchus; 
Figure 1. Flowchart of the study population. Patients affected by primary cancer followed up for malignant mesothelioma. EBRT, external beam 
radiotherapy.
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breast; stomach; rectum and rectosigmoid junction; cervix 
uteri; corpus uteri and uterus not otherwise specified; 
prostate; testis; penis and other male genital organs. After 
exclusion of subjects with missing information on radio-
therapy, surgery or county, or who had received radio-
therapy other than EBRT, we identified a cohort of 935,637 
patients that entered the main analysis. We observed 301 
incident mesothelioma cases in the study population: 265 
pleural, 32 peritoneal, and 4 cases in other or unknown 
sites.
Diagnostic techniques used to confirm the diagnosis of 
mesothelioma were: histology (n = 263, 87.4%); exfoliative 
cytology (n = 28, 9.3%); direct visualization (n = 1, 0.3%); 
radiography (n = 6, 2.0%); and clinical diagnosis (n = 2, 
0.7%). Quality of diagnosis was unknown for one case 
(0.3%).
A summary of the cohort (Table 2) reveals differences 
in use of EBRT by genders, calendar periods, and cancer- 
direct surgery. The use of EBRT was more frequent among 
females and increased over time. Also, irradiation was 
more common among nonoperated patients. Table S2 
presents the characteristics of the study population by 
primary cancer site. In our cohort, the percentage of 
irradiated patients ranged between 15.1% (stomach) and 
73.8% (larynx).
Table 3 presents the cause- specific HR of mesothelioma. 
We observed an increased risk of mesothelioma in any 
site among EBRT patients compared to nonirradiated 
subjects (fully adjusted HR = 1.34, 95% CI 1.04–1.74) 
and the estimate was higher after a minimum latency 
period of 10 years (fully adjusted HR = 1.58, 95% CI 
1.10–2.26). The risk of pleural mesothelioma was higher 
among irradiated subjects (fully adjusted HR for 
EBRT = 1.34, 95% CI 1.01–1.77), but there were no 
important differences between radiation doses (fully 
adjusted HR: scattered irradiation = 1.38, 95% CI 1.01–1.89; 
direct irradiation = 1.23, 95% CI 0.77–1.96). Again, the 
associations were stronger after 10 years from the irradia-
tion (fully adjusted HR for EBRT = 1.49, 95% CI 1.00–2.21). 
When investigating peritoneal mesothelioma, we found 
clear signs of an association with EBRT only for direct 
irradiation (age- and sex- adjusted HR = 2.20, 95% CI 
0.99–4.88; HR for latency periods of more than 
10 years = 3.28, 95% CI 1.14–9.43). As shown in Table 
S3, bivariate regression models revealed that age and sex 
were the most relevant confounders in the association 
between EBRT and peritoneal mesothelioma; furthermore, 
the other potential confounders selected a priori did not 
materially change the estimates for EBRT (Table S3).
As shown in Table 4, the SHR estimated through com-
peting risks models were lower than the cause- specific 
HR, suggesting that the clinical impact of the association 
between EBRT and mesothelioma was limited due to the 
high risk of death or incidence of other malignancies. 
Furthermore, the CIF of mesothelioma after 40 years from 
the primary diagnosis was very low both among irradiated 
and nonirradiated subjects (Fig. 2).
Table S4 presents the estimates for the association 
between the proxy exposure variable for asbestos and the 
risk of mesothelioma as a second malignancy. Compared 
to inhabitants of counties were the RR of primary meso-
thelioma was below 0.67, patients from high- risk counties 
showed a remarkable increase in the incidence of meso-
thelioma after a primary solid cancer. Indeed, we observed 
a well- shaped dose–response, with HR ranging from 2.11 
(county’s RR of mesothelioma between 0.67 and 0.90) to 
5.60 (RR of 1.50 or more).
Discussion
Our analysis demonstrated that EBRT is a risk factor 
for mesothelioma. The association was stronger for peri-
toneal mesothelioma and latency periods longer than 
Table 2. Characteristics of the study population at the diagnosis of pri-
mary cancer.
Characteristic
External beam radiotherapy
No Yes
(n = 593,949) (n = 341,688)
Age (years), mean (SD) 60.1 (12.2) 59.7 (12.2)
Gender
Female, n (%) 308,045 (61.2) 195,139 (38.8)
Male, n (%) 285,904 (66.1) 146,549 (33.9)
Race
White, n (%) 494,587 (63.8) 280,959 (36.2)
Black, n (%) 51,761 (62.1) 31,564 (37.9)
Other, n (%) 47,601 (62.0) 29,165 (38.0)
Year of diagnosis
1973–1977, n (%) 45,117 (75.4) 14,722 (24.6)
1978–1982, n (%) 50,548 (74.0) 17,803 (26.0)
1983–1987, n (%) 59,044 (70.3) 24,981 (29.7)
1988–1992, n (%) 85,077 (66.8) 42,298 (33.2)
1993–1997, n (%) 116,369 (62.7) 69,110 (37.3)
1998–2002, n (%) 118,052 (57.4) 87,593 (42.6)
2003–2007, n (%) 119,742 (58.4) 85,181 (41.6)
Cancer- direct surgery
no, n (%) 72,073 (41.0) 103,594 (59.0)
yes, n (%) 521,876 (68.7) 238,094 (31.3)
County’s mesothelioma relative risk
<0.67 64,072 (66.1) 32,792 (33.9)
0.67–0.90 232,655 (65.2) 124,213 (34.8)
0.91–1.09 126,269 (63.6) 72,204 (36.4)
1.10–1.49 147,659 (60.0) 98,416 (40.0)
≥1.50 23,294 (62.4) 14,063 (37.6)
Mesothelioma
no, n (%) 593,762 (63.5) 341,574 (36.5)
yes, n (%) 187 (62.1) 114 (37.9)
6 © 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
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10 years were associated with higher relative risks. We 
failed to demonstrate a dose–response between radiation 
dose and pleural mesothelioma risk; the association might 
be nonlinear and very low doses could still convey an 
increased risk. A competing risks analysis revealed that 
the impact of radiation- induced mesothelioma in our 
cohort was limited by the high risk of death or other 
second malignancies. The CIF of mesothelioma after 
40 years of observation was extremely low, suggesting 
that the clinical relevance of radiation- induced meso-
thelioma is limited.
Our findings are in line with our previous study that 
showed an increased risk of mesothelioma in any site 
(93% of cases were pleural) after EBRT for prostate cancer 
[6]. Although radiation- induced malignancies are usually 
expected to occur within the irradiated field (e.g., Baxter 
et al. [21]), even tissues located outside this area are 
significantly exposed to scattered radiation, as well as to 
leakage from the radiation source [22–24]. A dose of 
1–5 Gy has been estimated for tissues distant 3–10 cm 
from the irradiated field, while those located more than 
10 cm outside the irradiated area can receive doses of 
0.1–1 Gy.[14] These doses are in line with those studied 
among atomic bomb survivors, when an excess risk of 
solid cancers was demonstrated for exposure levels as low 
as 0.1–0.2 Gy [7]. In the same population, the risk of 
solid cancers after radiation exposure showed a linear 
dose–response only in the range 0–2 Gy, while the func-
tion flattened for higher doses [7]. Similarly, we did not 
document a higher risk of pleural mesothelioma for direct 
exposure compared to scattered irradiation. However, we 
did observe a considerably increased risk of peritoneal 
mesothelioma only after direct irradiation, but due to the 
limited number of cases we cannot rule out the possibility 
that the large difference in the estimates for scattered 
and direct radiation was a chance finding. We found that 
the risk of mesothelioma continues to increase with the 
latency period, in line with current knowledge on radiation- 
induced solid cancers [13].
Study­strength­and­limitations
To our best knowledge, this is the first study of the 
dose–response between EBRT and mesothelioma risk in 
a la large population. Furthermore, we conducted sepa-
rate analysis for pleural and peritoneal mesothelioma 
and we studied the role of the latency period. Our 
study does have limitations. The amount of information 
on potential confounders was limited and we cannot 
directly control our estimates for exposure to asbestos 
Figure 2. Cumulative incidence function of mesothelioma in any site; estimates from flexible parametric survival models for competing risks. 
*Cumulative incidence functions adjusted by age (60 years, mean value), sex (female, modal value), race (white, modal value), year of primary cancer 
diagnosis (1996, median value), primary cancer surgery (performed, modal value), and county’s mesothelioma relative risk (1.01, mean value).
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– which is always a concern when investigating meso-
thelioma. Hence, we derived a proxy measure of exposure 
to asbestos by modeling the RR of primary mesothelioma 
among males in the county of residence. Despite its 
obvious limitations, this variable was strongly associated 
with mesothelioma risk in our population (Table S4). 
Noteworthy, the estimates of interest (i.e., the HR for 
EBRT) showed only minor changes after the introduc-
tion of the county’s RR of mesothelioma in the mul-
tivariable models (data not shown). This finding suggests 
that our estimates were not strongly confounded by 
asbestos exposure. To further characterize the potential 
for unmeasured confounding, we conducted a target- 
adjustment sensitivity analysis to assess the difference 
in the prevalence of occupational exposure to asbestos 
by radiotherapy status necessary to explain the associa-
tions observed for latency periods of 10 or more years 
(Data S1). In the case of pleural mesothelioma, the 
prevalence of occupational exposure to asbestos should 
be 55% higher among irradiated subjects compared to 
nonirradiated (Table S5). Such a large difference seems 
implausible and, on the balance, we do not believe that 
unmeasured confounding asbestos exposure can entirely 
explain our findings. Another limitation of our study 
is the potential for detection bias, but we observed the 
higher HR of mesothelioma among irradiated patients 
after ten or more years from the primary diagnosis. A 
substantial difference in health monitoring among the 
studied groups is unlikely to have occurred so far from 
the primary diagnosis. Confounding by indication (i.e., 
primary cancer) might affect our estimates. To reduce 
the potential for this bias, we restricted the analyses to 
highly informative cancer sites (i.e., those frequently 
treated with EBRT and with at least one expected case 
of mesothelioma). Moreover, we explore the presence 
of within group correlation by fitting shared- frailty 
models, but we did not found evidence supporting the 
assumption of a random intercept. An obvious limita-
tion of our study is the wrong assignment of EBRT 
exposure in register data; however, this kind of nondif-
ferential misclassification is likely to bias the estimates 
of interest toward the null hypothesis. Finally, we could 
not investigate extremely long latency periods due to 
the limited time period covered by the SEER registries: 
our cohort included only eleven secondary mesothelioma 
cases occurred more than 20 years after the primary 
diagnosis. Hence, our study provides information only 
for relatively short (<20 years) latency periods. As 
asbestos- related mesothelioma is usually diagnosed dec-
ades after the first exposure, [1] we cannot rule out 
the hypothesis that the risk of radiation- induced meso-
thelioma might continue to increase for several years 
after the exposure to EBRT.
Conclusions
Our study shows that exposure to ionizing radiation – in 
particular to EBRT - might be a determinant of meso-
thelioma. Longer latency periods are associated with higher 
relative risks, whereas the dose–response relationship seems 
be nonlinear. Despite the etiological association, the clini-
cal impact of secondary mesothelioma after EBRT for a 
primary solid cancer is limited.
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